**Specifications tableSubject**Biochemistry, Genetics and Molecular Biology**Specific subject area**Genetics; Molecular biology; Molecular medicine; Cancer Research**Type of data**Tables**How data were acquired***NHGRI-EBI GWAS catalogueNCBI* database*GeneCards* database*Ensembl* database**Data format**RawFiltered**Parameters for data collection**The collection of VTE GWAS data (VTE variants' characterization, study population description and overall risk conferred by each variant in VTE GWAS) was made by screening the *NHGRI-EBI GWAS catalogue*. Regarding candidate gene and validation reports, data collection was performed by searching the NCBI database. As for the impact of VTE-associated genes in carcinogenesis, putative links with cancer hallmarks were established by searching the *NCBI, GeneCards and Ensembl* databases.**Description of data collection**For VTE GWAS data collection, no restriction was made regarding the origin and age of the population. We gathered only the genetic variants statistically associated with VTE susceptibility in the GWAS´ discovery phase (*P* \< 0.05). For candidate gene and validation reports, we only gathered the reports that analysed incident VTE among adults of European ancestry with no strong risk factors and performed before and after GWAS findings, respectively. In terms of the links between VTE-associated genes and cancer hallmarks, we gathered the information from reports that addressed this topic.**Data source location***NHGRI-EBI GWAS catalogueNCBI* database*GeneCards* database*Ensembl* database**Data accessibility**Data is provided in the article**Related review article**Tavares V., Pinto R., Assis J., Pereira D., Medeiros R. (2019). Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, <https://doi.org/10.1016/j.bbcan.2019.188331>

Value of the data {#sec0001a}
=================

•Given the existence of a tight and bilateral relationship between VTE and cancer, VTE-associated single nucleotide polymorphisms (SNPs) constitute potential cancer-related predictive and prognostic biomarkers that are currently in need.•Considering the growing incidence of VTE among cancer patients, with its underlying negative impact on patient prognosis, this dataset can benefit researchers and clinicians that work in the oncology field, who are interested in the genetic susceptibility for VTE, and how VTE-associated SNPs can be linked to cancer progression.•This database can be used for the development of several experiments as the majority of VTE genetic variants with a putative role in cancer progression have not been studied among cancer patients, particularly ovarian cancer patients who are frequently diagnosed with VTE and/or present a blood hypercoagulability state in the blood coagulation tests.

1. Data {#sec0001}
=======

[Table 1](#tbl0001){ref-type="table"} comprises the data obtained from GWAS performed to identify genetic variants that are associated with VTE susceptibility. [Table 2](#tbl0002){ref-type="table"} includes the data of a genome-wide search of pairwise SNP interactions associated with VTE risk. [Table 3](#tbl0003){ref-type="table"} encompasses data regarding previously reported candidate gene and validation reports of GWAS-identified SNPs that are associated with VTE risk. [Table 4](#tbl0004){ref-type="table"} includes putative links between VTE-associated genes and several cancer hallmarks.Table 1SNPs identified by VTE susceptibility GWAS.Table 1Report accession on NHGRI-EBI GWAS catalogueAssociated SNPsPopulationNo. cases/controls (combined)MAFLocusGene/VariantOverall riskAllelic OR (95% Cl)*P-value***GCST000354**rs2420371European ancestry419/1228 (Discovery phase)0.15[a](#tb1fn1){ref-type="table-fn"}1q24.2*F5*/intr2.27 (1.62; 3.18)[c](#tb1fn3){ref-type="table-fn"}8.08 × 10^−10^rs12081340.12[a](#tb1fn1){ref-type="table-fn"}1q24.2*CCDC181*/ intr2.29 (1.58; 3.32)[c](#tb1fn3){ref-type="table-fn"}3.47 × 10^−7^rs6571520.54[a](#tb1fn1){ref-type="table-fn"}chr9: 133,263,862[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.89 (1.51; 2.36)[c](#tb1fn3){ref-type="table-fn"}2.22 × 10^−13^rs5059220.52[a](#tb1fn1){ref-type="table-fn"}chr9: 133,273,813[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.91 (1.53; 2.39)[c](#tb1fn3){ref-type="table-fn"}1.48 × 10^−14^rs6300140.37[a](#tb1fn1){ref-type="table-fn"}9q34.2*ABO*/intr0.64 (0.51; 0.80)[c](#tb1fn3){ref-type="table-fn"}2.00 × 10^−7^rs2420371[¥](#tb1fn11){ref-type="table-fn"}European ancestry1150/801 (Replication phase I)0.21[a](#tb1fn1){ref-type="table-fn"}1q24.2*F5*/intr1.39 (1.17;1.64)[c](#tb1fn3){ref-type="table-fn"}3.00 × 10^−5^rs1208134[¥](#tb1fn11){ref-type="table-fn"}0.19[a](#tb1fn1){ref-type="table-fn"}1q24.2*CCDC181*/ intr1.57 (1.31; 1.88)[c](#tb1fn3){ref-type="table-fn"}2.89 × 10^−7^rs60250.011q24.2*F5*/mis2.01 (1.63; 2.48)[c](#tb1fn3){ref-type="table-fn"}9.91 × 10^−11^rs657152[§](#tb1fn12){ref-type="table-fn"}0.51[a](#tb1fn1){ref-type="table-fn"}chr9: 133,263,862[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.75 (1.51; 2.03)[c](#tb1fn3){ref-type="table-fn"}1.20 × 10^−13^rs505922[§](#tb1fn12){ref-type="table-fn"}0.49[a](#tb1fn1){ref-type="table-fn"}chr9: 133,273,813[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.81 (1.56; 2.11)[c](#tb1fn3){ref-type="table-fn"}3.72 × 10^−15^rs630014[§](#tb1fn12){ref-type="table-fn"}0.38[a](#tb1fn1){ref-type="table-fn"}9q34.2*ABO*/intr0.66 (0.57; 0.76)[c](#tb1fn3){ref-type="table-fn"}1.21 × 10^−8^rs81767190.349q34.2*ABO*/fra0.33 (0.26; 0.42)[c](#tb1fn3){ref-type="table-fn"}1.70 × 10^−18^rs81767500.059q34.2*ABO*/fra0.53 (0.38; 0.74)[c](#tb1fn3){ref-type="table-fn"}2.46 × 10^−4^rs2420371[¥](#tb1fn11){ref-type="table-fn"}European ancestry607/607 (Replicatio*n* phase II)0.10[a](#tb1fn1){ref-type="table-fn"}1q24.2*F5*/intr1.44 (1.07; 1.93)[c](#tb1fn3){ref-type="table-fn"}1.80 × 10^−3^rs60250.011q24.2*F5*/mis2.46 (1.55; 3.93)[c](#tb1fn3){ref-type="table-fn"}1.50 × 10^−4^rs657152[§](#tb1fn12){ref-type="table-fn"}0.47[a](#tb1fn1){ref-type="table-fn"}chr9: 133,263,862[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.58 (1.34; 1.87)[c](#tb1fn3){ref-type="table-fn"}5.19 × 10^−8^rs505922[§](#tb1fn12){ref-type="table-fn"}0.46[a](#tb1fn1){ref-type="table-fn"}chr9: 133,273,813[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.65 (1.39; 1.95)[c](#tb1fn3){ref-type="table-fn"}7.25 × 10^−9^rs630014[§](#tb1fn12){ref-type="table-fn"}0.38[a](#tb1fn1){ref-type="table-fn"}9q34.2*ABO*/intr0.63 (0.53; 0.74)[c](#tb1fn3){ref-type="table-fn"}5.01 × 10^−8^rs81767190.349q34.2*ABO*/fra0.53 (0.41; 0.69)[c](#tb1fn3){ref-type="table-fn"}2.21 × 10^−6^**GCST000621**rs3813948European ancestry419/1228 (*in silico* GWAS)0.09[a](#tb1fn1){ref-type="table-fn"}1q32.1*C4BPB*/nc--0.011rs38139481706/1379 (Replication phase)0.09[a](#tb1fn1){ref-type="table-fn"}1q32.1*C4BPB*/nc1.24 (1.00; 1.53)0.046**GCST001253**rs16861990European ancestry1542/1110 (Discovery phase)0.13[a](#tb1fn1){ref-type="table-fn"}1q24.2*NME7*/intr2.49[c](#tb1fn3){ref-type="table-fn"}-2.75 × 10^−15^rs12081340.13[a](#tb1fn1){ref-type="table-fn"}1q24.2*CCDC181*/ intr2.53[c](#tb1fn3){ref-type="table-fn"} -3.29 × 10^−16^rs24203710.15[a](#tb1fn1){ref-type="table-fn"}1q24.2*F5*/intr2.62[c](#tb1fn3){ref-type="table-fn"} -8.44 × 10^−19^rs20668650.28[a](#tb1fn1){ref-type="table-fn"}4q32.1*FGG*/inter1.55[c](#tb1fn3){ref-type="table-fn"} -1.17 × 10^−10^rs68254540.30[a](#tb1fn1){ref-type="table-fn"}4q31.3*FGA*/inter1.50[c](#tb1fn3){ref-type="table-fn"}-1.32 × 10^−9^rs100297150.12[a](#tb1fn1){ref-type="table-fn"}4q35.2*F11-ASII*intr**--**3.20 × 10^−9^rs20738280.32[a](#tb1fn1){ref-type="table-fn"}chr9: 133,261,737[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}**--**3.57 × 10^−9^rs6571520.49[a](#tb1fn1){ref-type="table-fn"}chr9: 133,263,862[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.70[c](#tb1fn3){ref-type="table-fn"}1.10 × 10^−18^rs5004980.33[a](#tb1fn1){ref-type="table-fn"}chr9: 133,273,232[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}--1.03 × 10^−12^rs5059220.49[a](#tb1fn1){ref-type="table-fn"}chr9: 133,273,813[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.85[c](#tb1fn3){ref-type="table-fn"}1.06 × 10^−23^rs6300140.38[a](#tb1fn1){ref-type="table-fn"}9q34.2*ABO*/intr0.63[c](#tb1fn3){ref-type="table-fn"}4.40 × 10^−14^rs4958280.36[a](#tb1fn1){ref-type="table-fn"}9q34.2*ABO*/rr1.64[c](#tb1fn3){ref-type="table-fn"}1.78 × 10^−14^rs1018827European ancestry1961/2338 (meta-analysis)[d](#tb1fn4){ref-type="table-fn"}0.071q24.2*F5*/intr2.522.41 × 10^−26^rs76590240.304q31.3*FGG*/inter1.531.93 × 10^−13^rs5059220.35chr9: 133,273,813[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.921.39 × 10^−34^rs37560080.324q35.2*F11*/inter1.406.46 × 10^−11^**GCST001557**rs602598.64% European ancestry (USA)1503/1459 (Discovery phase)0.011q24.2F5/mis3.75 (2.76; 4.60)1.68 × 10^−22^rs81767190.349q34.2*ABO*/fra1.47 (1.32; 1.64)5.68 × 10^−12^rs25190930.14chr9: 133,266,456[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.69 (1.48; 1.91)8.08 × 10^−16^rs4958280.169q34.2*ABO*/rr1.65 (1.46; 1.86)2.96 × 10^−16^rs7538157[¥](#tb1fn11){ref-type="table-fn"}\<0.011q24.2*BLZF1*/intr2.69 (2.09; 3.45)1.04 × 10^−14^rs16861990[¥](#tb1fn11){ref-type="table-fn"}0.061q24.2*NME7*/intr2.02 (1.66; 2.45)1.69 × 10^−12^rs20380240.131q24.2*SLC19A2*/nc1.53 (1.32; 1.78)1.12 × 10^−8^rs1799963\<0.0111p11.2*F2*/utr2.46 (1.70; 3.55)1.69 × 10^−6^rs602598.64% European ancestry (USA)1407/1418 (Replication phase)0.011q24.2*F5*/mis2.56 (1.97; 3.32)1.40 × 10^−12^rs81767190.349q34.2*ABO*/fra1.58 (1.40; 1.78)[e](#tb1fn5){ref-type="table-fn"}9.75 × 10^−14^[e](#tb1fn5){ref-type="table-fn"}rs25190930.14chr9: 133,266,456[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.85 (1.61; 2.13)[e](#tb1fn5){ref-type="table-fn"}1.37 × 10^−17^[e](#tb1fn5){ref-type="table-fn"}rs4958280.169q34.2*ABO*/rr1.76 (1.54; 2.01)[e](#tb1fn5){ref-type="table-fn"}3.60 × 10^−17^[e](#tb1fn5){ref-type="table-fn"}rs1799963\<0.0111p11.2*F2*/utr1.71 (1.12; 2.63)[e](#tb1fn5){ref-type="table-fn"}0.01[e](#tb1fn5){ref-type="table-fn"}rs168619900.061q24.2*NME7*/intr1.79 (1.47; 2.18)4.89 × 10^−9^1.17 (0.89;1.54)[e](#tb1fn5){ref-type="table-fn"}0.25[e](#tb1fn5){ref-type="table-fn"}rs20380240.131q24.2*SLC19A2*/nc0.77 (0.65;0.92)[e](#tb1fn5){ref-type="table-fn"}4.00 × 10^−3^[e](#tb1fn5){ref-type="table-fn"}**GCST002012**rs6427196European ancestry1618/44,499 (Discovery phase)0.091q24.2*F5/*utr1.82 (1.58; 2.10)[c](#tb1fn3){ref-type="table-fn"}1.97 × 10^−16^rs6876210.38chr9: 133,261,662[b](#tb1fn2){ref-type="table-fn"}*ABO/*intr[b](#tb1fn2){ref-type="table-fn"}1.37 (1.26;1.49)[c](#tb1fn3){ref-type="table-fn"}3.42 × 10^−14^rs42533990.264q35.2*F11/i*ntr1.15 (1.06; 1.24)[c](#tb1fn3){ref-type="table-fn"}7.59 × 10^−4^rs65360240.464q32.1*FGG/*interg0.79 (0.73; 0.87)[c](#tb1fn3){ref-type="table-fn"}4.04 × 10^−7^rs67646230.353p26.3*CNTN6/*interg1.23 (1.11; 1.38)[c](#tb1fn3){ref-type="table-fn"}9.56 × 10^−5^rs49790780.339q31.3*SUSD1/*intr1.31 (1.17; 1.47)[c](#tb1fn3){ref-type="table-fn"}2.46 × 10^−6^rs71645690.3315q13.3*OTUD7A/*syn0.84 (0.76; 0.92)[c](#tb1fn3){ref-type="table-fn"}3.54 × 10^−4^rs37338600.175q13.3*SV2C/*utr1.22 (1.09; 1.37)[c](#tb1fn3){ref-type="table-fn"}6.27 × 10^−4^rs6427196European ancestry3231/3536 (Replication phase)0.091q24.2*F5/*utr2.31 (2.04; 2.62)[c](#tb1fn3){ref-type="table-fn"}2.56 × 10^−38^rs6876210.38chr9: 133,261,662[b](#tb1fn2){ref-type="table-fn"}*ABO/*intr[b](#tb1fn2){ref-type="table-fn"}1.75 (1.62; 1.89)[c](#tb1fn3){ref-type="table-fn"}1.20 × 10^−44^rs42533990.264q35.2*F11/i*ntr1.32 (1.23; 1.43)[c](#tb1fn3){ref-type="table-fn"}2.07 × 10^−13^rs65360240.464q32.1*FGG/*interg0.81 (0.75; 0.87)[c](#tb1fn3){ref-type="table-fn"}5.59 × 10^−8^rs67646230.353p26.3*CNTN6/*interg1.14 (1.05; 1.24)[c](#tb1fn3){ref-type="table-fn"}2.00 × 10^−3^rs49790780.339q31.3*SUSD1/*intr1.11 (1.00; 1.24)[c](#tb1fn3){ref-type="table-fn"}4.70 × 10^−2^rs71645690.3315q13.3*OTUD7A/*syn0.88 (0.82; 0.95)[c](#tb1fn3){ref-type="table-fn"}2.00 × 10^−3^rs37338600.175q13.3*SV2C/*utr1.17 (1.05; 1.30)[c](#tb1fn3){ref-type="table-fn"}3.00 × 10^−3^rs6427196European ancestry4849/48,035 (Combined data of all nine studies)0.091q24.2*F5/*utr2.07 (1.89; 2.28)[c](#tb1fn3){ref-type="table-fn"}4.47 × 10^−51^rs6876210.38chr9: 133,261,662[b](#tb1fn2){ref-type="table-fn"}*ABO/*intr[b](#tb1fn2){ref-type="table-fn"}1.55 (1.47; 1.64)[c](#tb1fn3){ref-type="table-fn"}1.55 × 10^−52^rs42533990.264q35.2*F11/i*ntr1.24 (1.17; 1.31)[c](#tb1fn3){ref-type="table-fn"}2.78 × 10^−14^rs65360240.464q32.1*FGG/*interg0.80 (0.76; 0.85)[c](#tb1fn3){ref-type="table-fn"}1.75 × 10^−13^rs67646230.353p26.3*CNTN6/*interg1.18 (1.10; 1.26)[c](#tb1fn3){ref-type="table-fn"}1.57 × 10^−6^rs49790780.339q31.3*SUSD1/*intr1.21 (1.11; 1.30)[c](#tb1fn3){ref-type="table-fn"}3.06 × 10^−6^rs71645690.3315q13.3*OTUD7A/*syn0.87 (0.81; 0.92)[c](#tb1fn3){ref-type="table-fn"}3.27 × 10^−6^rs37338600.175q13.3*SV2C/*utr1.19 (1.10; 1.29)[c](#tb1fn3){ref-type="table-fn"}8.06 × 10^−6^**GCST002808**rs6025European ancestry7507/52,632 (Discovery phase)0.011q24.2*F5*/mis3.25 (2.91; 3.64)1.10 × 10^−96^rs45240.271q24.2*F5*/mis1.20 (1.14; 1.26)2.65 × 10^−11^rs20668650.304q32.1*FGG*/ inter1.24 (1.18; 1.31)1.03 × 10^−16^rs42534170.304q35.2*F11*/intr1.27 (1.22; 1.34)1.21 × 10^−23^rs5295650.37chr9: 133,274,084[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.55 (1.48; 1.63)4.23 × 10^−75^rs1799963\<0.0111p11.2*F2*/utr2.29 (1.75; 2.99)1.73 × 10^−9^rs60876850.3920q11.22*PROCR*/intr1.15 (1.10; 1.21)1.65 × 10^−8^rs46028610.398q23.1*ZFPM2*/intr1.20 (1.13; 1.27)3.48 × 10^−9^rs787077130.0510q22.1*TSPAN15*/intr1.28 (1.19; 1.39)5.74 × 10^−11^rs22889040.1819p13.2*SLC44A2*/mis1.19 (1.12; 1.26)1.07 × 10^−9^rs78707713European ancestry3009/2586 (Replication phase)0.0510q22.1*TSPAN15*/intr1.42 (1.24; 1.62)2.21 × 10^−7^rs22889040.1819p13.2*SLC44A2*/mis1.28 (1.16; 1.40)2.64 × 10^−7^rs4602861European ancestry10,516/55,218 (combined data)0.398q23.1*ZFPM2*/intr--5.04 × 10^−7^rs787077130.0510q22.1*TSPAN15*/intr--1.67 × 10^−16^rs22889040.1819p13.2*SLC44A2*/mis--2.75 × 10^−15^**GCST003377**rs62322307[\#](#tb1fn13){ref-type="table-fn"}West African Ancestry[f](#tb1fn6){ref-type="table-fn"} (80%) European and Asian ancestry146/432 (Discovery phase)0.15[a](#tb1fn1){ref-type="table-fn"}4q22.2*ATOH1*/inter2.79 (1.80; 4.30)2.25 × 10^−7^rs736923100.15[a](#tb1fn1){ref-type="table-fn"}7p12.3*IGFBP3*/inter3.04 (2.00;4.70)1.73 × 10^−9^rs58952918[\#](#tb1fn13){ref-type="table-fn"}0.17[a](#tb1fn1){ref-type="table-fn"}18p11.32*AP005230.1*/ intr2.48 (1.70; 3.70)1.07 × 10^−8^rs284969960.17[a](#tb1fn1){ref-type="table-fn"}18p11.32*AP005230.1*/ intr2.44 (1.60; 3.60)1.13 × 10^−8^rs21449400.31[a](#tb1fn1){ref-type="table-fn"}20p11.21*THBD*, CD93/inter2.18 (1.60; 2.90)3.52 × 10^−7^rs2567617[\#](#tb1fn13){ref-type="table-fn"}0.31[a](#tb1fn1){ref-type="table-fn"}20p11.21*THBD*, CD93/inter2.17 (1.60; 2.90)4.01 × 10^−7^rs19980810.27[a](#tb1fn1){ref-type="table-fn"}20p11.21*THBD*, CD93/inter2.28 (1.60; 3.10)5.17 × 10^−7^rs6876210.38chr9: 133,261,662[b](#tb1fn2){ref-type="table-fn"}*ABO/*intr[b](#tb1fn2){ref-type="table-fn"}1.55 (1.20; 2.00)2.00 × 10^−3^rs5059220.35chr9: 133,273,813[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.52 (1.20; 2.00)2.00 × 10^−3^rs6571520.39chr9: 133,263,862[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.39 (1.10; 1.80)0.03rs73692310West African Ancestry[f](#tb1fn6){ref-type="table-fn"} (77%) European and Asian ancestry94/65 (Replication phase)0.09[a](#tb1fn1){ref-type="table-fn"}7p12.3*IGFBP3*/inter1.27 (0.04; 2.70)0.60rs284969960.13[a](#tb1fn1){ref-type="table-fn"}18p11.32*AP005230.1*/ intr1.34 (0.60; 2.60)0.45rs21449400.35[a](#tb1fn1){ref-type="table-fn"}20p11.21*THBD, CD93*/inter1.89 (1.10; 3.30)0.02rs19980810.30[a](#tb1fn1){ref-type="table-fn"}20p11.21*THBD, CD93*/inter1.94 (1.10; 3.50)0.02rs73692310West African Ancestry[f](#tb1fn6){ref-type="table-fn"} (79%) European and Asian ancestry240/497 (Combined data)0.027p12.3*IGFBP3*/inter--2.48 × 10^−8^rs284969960.0318p11.32*AP005230.1*/ intr--6.37 × 10^−8^rs21449400.1220p11.21*THBD, CD93*/inter--1.88 × 10^−8^rs19980810.1120p11.21*THBD, CD93*/inter--4.62 × 10^−8^**GCST003390**rs6025European ancestry6135/252,827 (Discovery phase)0.011q24.2*F5*/mis2.93 (2.72; 3.15)3.60 × 10^−137^rs76540930.314q32.1*FGG*/inter1.22 (1.17; 1.27)2.00 × 10^−19^rs44448780.324q35.2*F11-ASI*/intr0.81 (0.78; 0.84)7.00 × 10^−28^rs1799963\<0.0111p11.2*F2*/utr0.51 (0.46; 0.58)1.30 × 10^−24^rs342349890.3920q11.22*PROCR*/intr0.89 (0.85; 0.92)6.70 × 10^−9^rs5295650.37chr9: 133,274,084[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}0.72 (0.70; 0.75)7.10 × 10^−63^rs97978610.2119p13.2*SLC44A2*/ intr1.15 (1.09; 1.20)6.10 × 10^−9^rs1142091710.24Xq28*FUNDC2*/nc1.15 (1.11; 1.20)7.00 × 10^−13^rs727985440.012p21*COX7A2L*/intr0.73 (0.65; 0.82)1.90 × 10^−7^rs174906260.0410q22.1*TSPAN15*/intr1.17 (1.10; 1.24)2.90 × 10^−7^rs1130926560.016p24.1*TMEM170B*/*ADTRP*/inter0.73 (0.65; 0.82)4.40 × 10^−7^rs609427120.063p11.1*EPHA3*/inter1.21 (1.12; 1.31)8.00 × 10^−7^rs114209171European ancestry26,112 participants (Replication phase)0.24Xq28*FUNDC2*/nc1.08 (1.02; 1.14)0.01**GCST004012**rs1304029European ancestry212 children with VTE / 424 parents and siblings (Discovery phase)0.486q13*B3GAT2*/intr0.48 (0.36; 0.65)2.00 × 10^−6^[h](#tb1fn8){ref-type="table-fn"}rs92938580.266q13*RIMS1*/intr0.48 (0.34; 0.67)8.00 × 10^−6^[h](#tb1fn8){ref-type="table-fn"}rs27483310.416q13*B3GAT2*/rr0.49 (0.36; 0.67)1.80 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs104989100.126q14.1*LOC105377862/*intr[b](#tb1fn2){ref-type="table-fn"}2.21 (1.47; 3.31)6.89 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs9149580.231p22.1*ABCA4*/intr0.50 (0.36; 0.70)1.80 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs45290130.284q21.3*MAPK10*/intr0.53 (0.39; 0.72)2.00 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs99575190.2718q23-/inter0.46 (0.32; 0.68)2.10 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs18655900.312q22.1*THSD7B*/intr1.97 (1.44; 2.68)2.40 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs96065340.17chr22: 16,916,985[b](#tb1fn2){ref-type="table-fn"}*IGKV2OR22-4*/rr0.43 (0.29; 0.63)3.30 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs4958280.169q34.2*ABO*/rr--6.44 × 10^−4^rs5059220.35chr9: 133,273,813[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}--4.03 × 10^−4^rs6571520.39chr9: 133,263,862[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.77 (1.34; 2.32)3.44 × 10^−5^rs131462720.444q35.1*CYP4V2*/miss--9.58 × 10^−4^rs9254510.294q35.2*F11/*intr--2.76 × 10^−3^rs111287900.063p24.3*RFTN1*/intr2.95 (1.78; 4.90)3.40 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs47921190.2117p12*SHISA6*/Intr0.51 (0.37; 0.71)3.50 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs93997700.486q16.3-/inter0.55 (0.42; 0.74)4.00 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs175763720.271p22.1*TGFBR3*/intr1.84 (1.37; 2.47)4.57 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs102470530.257p15.2-/inter0.53 (0.39; 0.72)5.35 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs6364340.346q12*EYS*/intr1.79 (1.34; 2.39)5.35 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs101901780.312q22.1*THSD7B*/intr1.91 (1.40; 2.62)6.15 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs50148720.122p16.3*LOC730100*/ Intr[b](#tb1fn2){ref-type="table-fn"}0.46 (0.32; 0.68)6.21 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs38236060.047q11.21*TPST1*/intr--6.27 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs15652420.1115q26.1*LOC105370982*/intr[b](#tb1fn2){ref-type="table-fn"}0.44 (0.29; 0.67)7.23 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs19580590.3114q13.1*NPAS3*/intr0.45 (0.31; 0.67)7.28 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs15218820.232q33.1*KIAA2012*/intr2.13 (1.46; 3.11)7.48 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs177817930.0512q15*MRPL40P1*/ inter0.38 (0.23; 0.63)7.81 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs47753840.3115q22.2*AC104574.2*/ intr0.41 (0.26; 0.65)8.16 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs19486500.3315q14*DPH6-DT*/intr1.84 (1.34; 2.51)8.71 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs4369850.345q12.1*C5orf64*/intr0.58 (0.44; 0.76)9.13 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs49264480.471q44*SCCPDH*/intr0.57 (0.43; 0.76)9.38 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs111536260.226q22.1*FAM162B*/ inter1.85 (1.34; 2.54)9.49 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs22148100.267p15.2-/inter0.54 (0.40; 0.74)9.62 × 10^−5^[h](#tb1fn8){ref-type="table-fn"}rs2748331European ancestry413 children/ 826 parents and siblings (combined data of discovery phase and replication phase I)0.416q13*B3GAT2*/rr--7.88 × 10^−7^rs94463400.236q13*B3GAT2*/ Inter--1.48 × 10^−3^rs104989100.126q14.1*LOC105377862/*intr[b](#tb1fn2){ref-type="table-fn"}--5.74 × 10^−5^rs2748331European ancestry651 adults with VTE/ 1356 controls (Replication phase II)0.416q13*B3GAT2*/rr1.20 (1.02; 1.40)0.02[g](#tb1fn7){ref-type="table-fn"}rs13040290.486q13*B3GAT2*/intr1.18 (1.02; 1.36)0.03[g](#tb1fn7){ref-type="table-fn"}**GCST004068**rs138916004[Ж](#tb1fn14){ref-type="table-fn"}African ancestry (African-Americans)393/4941 (Discovery phase)\< 0.0112q14.3*LEMD3*/intr3.17 (2.13; 4.72)[j](#tb1fn9){ref-type="table-fn"}1.27 × 10^−8^[j](#tb1fn9){ref-type="table-fn"}rs3804476[Ж](#tb1fn14){ref-type="table-fn"}0.286p25.1*LY86*/intr1.83 (1.48; 2.26)[j](#tb1fn9){ref-type="table-fn"}1.97 × 10^−8^[j](#tb1fn9){ref-type="table-fn"}rs142143628[Ж](#tb1fn14){ref-type="table-fn"}\< 0.018q12.2*LOC100130298*/intr[b](#tb1fn2){ref-type="table-fn"}4.97 (2.80; 8.83)[j](#tb1fn9){ref-type="table-fn"}4.35 × 10^−8^[j](#tb1fn9){ref-type="table-fn"}rs60250.011q24.2*F5*/mis5.00 (2.02; 11.03)[j](#tb1fn9){ref-type="table-fn"}2.00 × 10^−4^[j](#tb1fn9){ref-type="table-fn"}rs81767460.159q34.2*ABO*/mis1.33 (1.09; 1.62)[j](#tb1fn9){ref-type="table-fn"}5.00 × 10^−3^[j](#tb1fn9){ref-type="table-fn"}rs81767190.349q34.2*ABO*/fra1.30 (1.11; 1.53)[j](#tb1fn9){ref-type="table-fn"}2.00 × 10^−3^[j](#tb1fn9){ref-type="table-fn"}rs77121243[β](#tb1fn15){ref-type="table-fn"}0.0311p15.4*HBB*/miss1.51 (1.11; 2.06)9.00 × 10^−3^**GCST004256**rs6025European ancestry3290/116,868 (Discovery phase)0.011q24.2*F5*/mis3.49 (2.96; 4.11)7.10 × 10^−50^rs20668650.304q32.1*FGG*/inter1.21 (1.15; 1.29)3.10 × 10^−11^rs42534160.414q35.2*F11*/intr1.18 (1.12; 1.24)2.00 × 10^−10^rs25190930.14chr9: 133,266,456[b](#tb1fn2){ref-type="table-fn"}*ABO*/intr[b](#tb1fn2){ref-type="table-fn"}1.41 (1.32; 1.50)6.00 × 10^−26^rs81766450.389q34.2*ABO*/intr1.28 (1.22; 1.35)4.40 × 10^−21^rs1799963\<0.0111p11.2*F2*/utr2.63 (2.03; 3.40)4.90 × 10^−13^rs31365160.2811p11.2*F2*/intr1.10 (1.04; 1.15)[k](#tb1fn10){ref-type="table-fn"}3.30 × 10^−4^[k](#tb1fn10){ref-type="table-fn"}rs46028610.398q23.1*ZFPM2*/intr1.08 (1.03; 1.15)4.50 × 10^−3^rs4602861European ancestry10,516/55,218 (Replication phase)0.398q23.1*ZFPM2*/intr1.13 (1.08; 1.19)5.04 × 10^−7^rs31365160.2811p11.2*F2*/intr1.10 (1.06; 1.15)[k](#tb1fn10){ref-type="table-fn"}5.65 × 10^−6^[k](#tb1fn10){ref-type="table-fn"}rs4602861European ancestry13,806/ 172,086 (combined data)0.398q23.1*ZFPM2*/intr1.11 (1.07; 1.15)4.88 × 10^−10^rs31365160.2811p11.2*F2*/intr1.10 (1.06; 1.13)[k](#tb1fn10){ref-type="table-fn"}7.60 × 10^−9^[k](#tb1fn10){ref-type="table-fn"}[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17]Table 2Genome-wide search for VTE-associated pairwise SNP interactions.Table 2ReportPairwise SNP interactions[++](#tb2fn1){ref-type="table-fn"}PopulationNo. cases/controls (combined)MAFLocusGene/VariantOverall riskOR*P-value***GCST001913**rs493014European ancestry1953/2338 (Meta analysis of two previous GWAS)0.309q34.2*SURF6*/Inter1.646.00 × 10^−11^rs8860900.329q34.2*SURF6*/misrs13364720.401p31.3*AK4*/utr1.544.24 × 10^−10^0.386p12.1*HMGCLL1*/interrs4715555rs3809040.298q24.3*ZC3H3*/intr1.674.51 × 10^−10^rs80860280.3018p11.22*PIEZO2*/utrrs68159160.094q34.3*TENM3-AS1*/ inter2.106.84 × 10^−10^rs60923260.4720q13.31*FAM209B*/interrs22820150.4110q26.13*AL160290.2*/intr1.508.36 × 10^−10^rs130504540.4221q21.3*AP001595.1*/ interrs76487040.333p22.3*TRIM71*/rr1.569.89 × 10^−10^rs48686440.495q35.2*RNF44*/interrs19853170.419q33.1*AL445644.1*/inter0.661.32 × 10^−9^rs8276370.4610p14*AC044784.1*/interrs23217440.1013q13.2*RFC3*/inter0.491.38 × 10^−9^rs64975400.4216p13.2*GRIN2A*/intrrs3151220.3012q15*YEATS4*/intr2.051.42 × 10^−9^rs8844830.1215q23*TLE3*/interrs14233860.205q12.1*LRRC70*/inter1.731.63 × 10^−9^rs64916790.2913q33.1*FGF14*/intrrs77146700.445q13.2*ARHGEF28*/miss1.521.75 × 10^−9^rs128807350.3514q12*AL390334.1*/intrrs93926530.286p25.1*PPP1R3G*/inter1.741.83 × 10^−9^rs77809760.197p21.2*DGKB*/interrs98041280.261p36.13*IGSF21*/inter1.711.90 × 10^−9^rs47843790.2416q12.2*IRX3*/interrs13645050.327q32.3*PLXNA4*/ intr1.802.10 × 10^−9^rs12046600.1620q11.22*UQCC1*/intrrs22880730.292q23.3*FAM228A/*miss1.602.11 × 10^−9^rs107710220.3412p12.1*SOX5*/intrrs13672280.442p16.1*EFEMP1*/intr1.492.20 × 10^−9^rs39050750.4013q33.3*FAM155AIT1*/ intrrs5364770.431q43*CHRM3*/intr0.632.93 × 10^−9^rs19379200.2710p15.1*AKR1C2*/interrs27102010.067q36.2*ACTR3B* /inter0.403.30 × 10^−9^rs37802930.359q21.2*GNA14*/intrrs125412540.348p22*DLC1*/intr1.653.33 × 10^−9^0.2315q23*TLE3*/interrs305009rs45079750.291q25.2*PAPPA2*/intr0.653.58 × 10^−9^rs99145180.4717p13.1*GSG1L2*/intrrs27710510.379q33.1-/inter0.673.82 × 10^−9^rs8276370.4610p14-/interrs105160890.315q35.1*SMIM23*/inter0.633.86 × 10^−9^rs110729300.2915q25.1*ARNT2*/interrs105041300.148q11.22*PCMTD1*/intr1.884.46 × 10^−9^rs28473510.3118p11.22*APCDD1*/interrs3184970.496p25.2*AL133351.3*/nc0.434.54 × 10^−9^rs70192590.079q21.2*PSAT1*/interrs66952230.131p22.3*WDR63*/intr1.864.70 × 10^−9^rs17635100.396q23.2*SGK1*/Intrrs13367080.2513q33.1*FGF14-IT1*/intr0.584.85 × 10^−9^rs14233860.205q12.1*CKS1BP3*/interrs67713160.133p13*LINC00877*/intr2.135.26 × 10^−9^rs109864320.179q33.3*OLFML2A*/intrrs6649100.303q21.3*MGLL*/intr1.506.63 × 10^−9^0.4615q22.2*RORA*/intrrs877228rs99454280.3018q22.3*FBXO15*/intr0.626.88 × 10^−9^rs48235350.2722q13.32*FAM19A5*/interrs19103580.235q14.2*C5orf17*/inter2.037.14 × 10^−9^rs99815950.1121q22.2*BRWD1*/intrrs67717250.273q26.31*NAALADL2*/intr2.228.60 × 10^−9^rs105072460.0912q24.21*TBX5*/intrrs168657170.282p25.2*RSAD2*/intr1.568.82 × 10^−9^rs20095790.3620q12-/interrs20283850.1612q23.1*AC007513.1*/intr1.698.82 × 10^−9^rs20382270.3816p13.3*RAB11FIP3*/intrrs104761600.205q35.2*SFXN1*/inter0.629.09 × 10^−9^rs17074200.488p23.2-/interrs9715720.321q25.3*TSEN15*/intr0.429.30 × 10^−9^rs108281510.0710p12.31*NEBL*/intrrs68584300.214q34.1*ADAM29*/intr1.629.67 × 10^−9^rs48002500.4018q11.2*TAF4B*/intrrs4676500.375q15*RGMB*/inter0.679.91 × 10^−9^rs71537490.4414q23.1*LINCO1500*/ intr[^18]Table 3SNPs reported by VTE GWAS in European populations and their analysis in previously reported candidate gene studies or validation studies also in European populations.Table 3GeneSNPType of ReportNo. cases/controls\
(combined)MAF (cases)OR (95% CI)*P*-valueReferences*F5*rs6025Candidate gene approach471/4740.01[\*](#tb3fn1){ref-type="table-fn"}6.50 (1.80--23.00) (GG vs. AG)\<0.05[@bib0001]rs4524Candidate gene approach1488/14390.25[⁎⁎](#tb3fn2){ref-type="table-fn"}0.77 (0.68--0.87)2.51 × 10^−5^[@bib0002]rs1018827Validation1040/16,9360.07[\*](#tb3fn1){ref-type="table-fn"}1.53 (1.29--1.79) (AA vs. AG)6.53 × 10^−6^[@bib0003]rs6427196Validation1040/16,9360.09[\*](#tb3fn1){ref-type="table-fn"}1.51 (1.28--1.78) (CC vs. CG)9.21 × 10^−6^[@bib0003]rs2420371[Ϫ](#tb3fn3){ref-type="table-fn"}----------*F2*rs1799963Candidate gene approach471/474\<0.01[\*](#tb3fn1){ref-type="table-fn"}2.80 (1.40--5.60)\<0.05[@bib0004]rs3136516Candidate gene approach428/7950.28[\*](#tb3fn1){ref-type="table-fn"}1.50 (1.00--2.20)\<0.05[@bib0005]*FGB/FGA/FGG*rs2066865Candidate gene approach471/4710.30[\*](#tb3fn1){ref-type="table-fn"}2.40 (1.50--3.90)0.002[@bib0006]rs6825454Candidate gene approach419/12280.31--2.80 × 10^−4^[@bib0007]rs7659024Validation1040/16,9360.30[\*](#tb3fn1){ref-type="table-fn"}1.40 (1.09--1.78) (AA vs. GG)3.03 × 10^−2^[@bib0003]rs6536024Validation1040/16,9360.46[\*](#tb3fn1){ref-type="table-fn"}**--0.23**[@bib0003]rs7654093[ф](#tb3fn4){ref-type="table-fn"}----------*F11*rs3756008Candidate gene approach1837/2204--1.27 (1.16--1.38)\<0.05[@bib0008]rs4253399Candidate gene approach1488/14390.41[⁎⁎](#tb3fn2){ref-type="table-fn"}1.28 (1.15--1.43)6.33 × 10^.6^[@bib0002]rs4253417----------rs4444878----------rs4253416----------*ABO*rs2519093Candidate gene approach1488/14390.24[⁎⁎](#tb3fn2){ref-type="table-fn"}1.68 (1.48--1.91)8.08 × 10^.16^[@bib0002]rs505922Validation1040/16,9360.35[\*](#tb3fn1){ref-type="table-fn"}1.78 (1.46--2.15) (CC vs. TT)5.17 × 10^−11^[@bib0003]rs630014Validation1040/16,9360.42[⁎⁎](#tb3fn2){ref-type="table-fn"}0.75 (0.67--0.84)2.67 × 10^−7^[@bib0002]*ABO*rs8176719Validation1040/16,9360.42[⁎⁎](#tb3fn2){ref-type="table-fn"}1.47 (1.32--1.64)5.68 × 10^−12^[@bib0002]Validation96/1480.481.62 (1.09--2.38)0.015[@bib0009]rs687621Validation1040/16,9360.38[\*](#tb3fn1){ref-type="table-fn"}1.74 (1.43--2.10) (AA vs. GG)5.45 × 10^.10^[@bib0003]rs495828Validation1040/16,9360.16[\*](#tb3fn1){ref-type="table-fn"}2.09 (1.64--2.63) (GG vs. TT)1.72 × 10^.10^[@bib0003]rs8176750----------rs657152----------rs529565----------rs8176645[Ж](#tb3fn5){ref-type="table-fn"}----------*C4BPB*rs3813948Validation1433/14020.07**--0.25**[@bib0010]*NME7*rs16861990Validation1040/16,9360.06[\*](#tb3fn1){ref-type="table-fn"}4.11 (2.14--7.33) (CC vs. AA)2.90 × 10^−7^[@bib0003]*PROCR*rs6087685Validation1040/16,9360.39[\*](#tb3fn1){ref-type="table-fn"}--**0.92**[@bib0003]rs34234989[Ɨ](#tb3fn6){ref-type="table-fn"}----------*TSPAN15*rs78707713Validation1040/16,9360.05[\*](#tb3fn1){ref-type="table-fn"}0.77 (0.66--0.91) (TT vs. TC)6.22 × 10^−3^[@bib0003]rs17490626[Ʊ](#tb3fn7){ref-type="table-fn"}----------*ZFPM2*rs4602861----------*SLC44A2*rs2288904Validation1040/16,9360.18[\*](#tb3fn1){ref-type="table-fn"}0.63 (0.44--0.89) (AA vs. GG)2.42 × 10^−2^[@bib0003]rs9797861[¥](#tb3fn8){ref-type="table-fn"}----------*SLC19A2*rs2038024----------*CCDC181*rs1208134----------*CNTN6*rs6764623----------*SUSD1*rs4979078----------*OTUD7A*rs7164569----------*SV2C*rs3733860----------*FUNDC2*rs114209171----------*COX7A2L*rs72798544----------*--*rs113092656----------*EPHA3*rs60942712----------[^19][^20][^21][^22][^23][^24][^25][^26][^27]Table 4VTE related-genes reported by GWAS and their putative links with cancer hallmarks.Table 4GenesHUGO nomenclatureMolecular processes that promote carcinogenesisPotential cancer hallmarks*F5Coagulation Factor V*Generation of thrombinMetastasis, angiogenesis, immune evasion and apoptosis [@bib0011]*CCDC181* (*C1orf114*)*Coiled-Coil Domain Containing 181*Despite the unknown role in carcinogenesis, this gene is frequently methylated in patients with prostate cancer [@bib0012]Genome instability and mutation*ABOABO Blood Group*Activation of adhesion molecules [@bib0013]Inflammation, immune evasion and metastasis \[[@bib0013], [@bib0014]\]Regulation of plasmatic levels of von Willebrand factor (vWF) [@bib0011]Angiogenesis and apoptosis [@bib0015]*C4BPBComplement Component 4 Binding Protein Beta*Inactivation of protein S, which is an important cofactor to activated protein C and constitutes a ligand for the Axl family of receptor tyrosine kinases \[[@bib0016], [@bib0017]\]Inflammation and apoptosis [@bib0016] Proliferation signalling, invasion and apoptosis through Axl receptor tyrosine kinase signalling [@bib0018]*NME7NME/NM23 Family Member 7*Embryonic Stem Cell Renewal [@bib0019]Metastasis*FGB/FGG/FGAFibrinogen Beta Chain/ Fibrinogen Gamma Chain/ Fibrinogen Alpha Chain*Formation of fibrin clotAngiogenesis [@bib0011]Immune response [@bib0020]Immune evasion and inflammationAugmentation of the proliferative effect of fibroblast growth factor‐2 (FGF‐2) [@bib0021]Proliferative signalling and angiogenesis [@bib0021]*F11Coagulation Factor XI*Generation of Factor XaApoptosis [@bib0022]Generation of thrombinMetastasis, angiogenesis, immune evasion and apoptosis [@bib0011]*SLC19A2Solute Carrier Family 19 Member 2*MetabolismCancer metabolism*F2Coagulation Factor II, thrombin*Generation of thrombinMetastasis, angiogenesis, immune evasion and apoptosis [@bib0011]*CNTN6Contactin 6*Activating of Notch signalling pathway [@bib0023] Mediation of cell surface interactionsProliferative signalling and metastasis [@bib0011]*OTUD7AOTU Deubiquitinase 7A*Modulation of nuclear factor kappa B (NF-κB) expression through interaction with TNF receptor associated factor 6 (TRAF6)Metastasis [@bib0024]*SV2CSynaptic Vesicle Glycoprotein 2C*Modulation of dopamine release [@bib0025]Apoptosis and inflammation [@bib0026]*SUSD1Sushi Domain Containing 1*Unknown role in carcinogenesisunknown*PROCRProtein C Receptor*Protein C pathwayProliferative signalling, invasion, metastasis, apoptosis and immune evasion [@bib0027] Angiogenesis [@bib0028]*ZFPM2* (*FOG2*)*Zinc Finger Protein, FOG Family Member 2*GATA transcriptional networkApoptosis, invasion and inflammation [@bib0029]Angiogenesis [@bib0030]*TSPAN15Tetraspanin 15*Mediates signal transduction events that play a role in the regulation of cell activation, growth, development and motility.Metastasis [@bib0031]*SLC44A2Solute Carrier Family 44 Member 2*MetabolismCancer metabolism*FUNDC2FUN14 Domain Containing 2*Modulation of platelet survival [@bib0032]Metastasis, angiogenesis and immune evasion [@bib0033]*COX7A2LCytochrome C Oxidase Subunit 7A2 Like*Regulation of oxidative phosphorylationCancer metabolism*EPHA3EPH Receptor A3*Regulation of developmental events\
Regulation of cytoskeletal organization, cell-cell adhesion and cell migrationInvasion and metastasis [@bib0034]\
Angiogenesis [@bib0035]*B3GAT2Beta-1,3-Glucuronyltransferase 2*Mismatch repair deficiency [@bib0036]Genome instability and mutation*THBDThrombomodulin*Protein C pathway\
Regulation of adhesion molecules [@bib0037]Angiogenesis [@bib0028]\
Invasion and metastasis [@bib0037]*LEMD3* (*MAN1*)*LEM Domain Containing 3*Regulation of transforming growth factor-beta (TGF-beta) signalling at the inner nuclear membraneProliferative signalling, invasion and apoptosis [@bib0038]\
Immune evasion [@bib0039]*LY86* (*MD-1)Lymphocyte Antigen 86*Innate Immune SystemInflammation*LOC100130298HCG1816373-Like*Unknown role in carcinogenesisUnknown[^28]

2. Experimental design, materials and methods {#sec0002}
=============================================

(1)GWAS addressing VTE susceptibility:

All SNPs statistically associated (*P* \< 0.05) with susceptibility to VTE (deep vein thrombosis, pulmonary embolism or both) were gathered by screening *NHGRI-EBI GWAS catalogue* and respective articles. No restriction was made regarding the origin and age of the population. In total, 12 VTE GWAS were collected, including ten in populations of European ancestry (one searching for pairwise SNP interactions associated with disease risk and one performed to determine the genetic factors of paediatric VTE) and two in Afro-American populations ([Fig. 1](#fig0001){ref-type="fig"}).(2)Other reports reporting VTE-associated SNPs:Fig. 1Schematic diagram of data collection.Fig. 1

After gathering all GWAS-identified SNPs associated with VTE risk, data regarding validation and candidate gene reports that stated the same associations were also collected, using the NCBI database, in order to confirm the GWAS findings ([Fig. 1](#fig0001){ref-type="fig"}). Only SNPs reported by VTE GWAS among adults of European ancestry were considered. Hence, only validation and candidate gene reports with adults of European ancestry with incident VTE and with no strong risk factors were taken into account. To our best knowledge, the majority of VTE GWAS-reported SNPs are currently lacking validation.(3)Putative links between VTE-associated genes and cancer hallmarks:

A vast search using *NCBI, GeneCards* and *Ensembl* databases ([Fig. 1](#fig0001){ref-type="fig"}) was made to collect data concerning VTE-associated genes and how they may be implicated in many cancer-related processes that contribute to cancer growth and progression.
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[^1]: The data shown in [Table 1](#tbl0001){ref-type="table"} concerning locus, type of genetic variant, as well as MAF values for all populations were obtained on the \"Ensembl\" database. For intergenic variants, the nearest gene was indicated.

[^2]: **MAF**: minor allele frequency; **OR**: odds ratio; **Inter**: Intergenic variant, **Intr**: Intronic variant, **Mis**: missense variant, **Fra**: frameshift variant, **Nc**: non coding transcript exon variant, **Syn**: synonymous variant, **UTR**: 3 prime UTR variant, **RR:** regulatory region variant.

[^3]: MAF values for cases in the Report

[^4]: Data obtained from "NCBI" database

[^5]: OR/RR associated with the minor allele

[^6]: 99 SNPs reached genome-wide significant (p \< 2 × 10^−8^), but only the hit SNPs of each locus (*F5, FGG, F11* and *ABO*) were included in the table

[^7]: Data after adjusting for rs6025

[^8]: SNPs predominantly found in populations of African descent

[^9]: After Bonferroni correction, the *P*-values became insignificant

[^10]: *P*-values of permutation testing

[^11]: After adjusting for sickle cell risk variant (*HBB* rs77121243-T allele) and other cofactors

[^12]: After adjusting for rs1799963.

[^13]: SNPs not significantly associated with VTE risk after adjusting for rs6025

[^14]: SNPs not significantly associated with VTE risk after adjusting for *ABO* blood group (rs8176719 and rs8176750)

[^15]: SNPs not tested in replication cohort due to high LD or due to failed assay

[^16]: SNPs further replicated using parametric bootstrap, internal cross-validation and meta-analysis methods

[^17]: SNP merged into rs334 according to "NCBI" database

[^18]: The interactions did not reach the Bonferroni correction for the number of investigated interactions; **MAF** -- minor allele frequency**; OR** -- odds ratio

[^19]: **MAF**: minor allele frequency**; OR**: odds ratio.

[^20]: MAF values obtained from "Ensembl" database

[^21]: Total MAF in the report (cases and controls)

[^22]: SNP in high LD with rs6427196, particularly for European ancestry populations (r^2^\>0.81), according to "Ensembl" database

[^23]: SNP in high LD with rs2066865 for all populations according to "Ensembl" database (r^2^\>0.81)

[^24]: SNP in high LD with rs8176719, particularly for European ancestry populations (r^2^\>0.90), according to "Ensembl" database

[^25]: SNP in high LD with rs6087685 for all populations according to "Ensembl" database (r^2^\>0.86, except in Kenya population)

[^26]: SNP in high LD with rs78707713 for most populations, particularly the European ancestry populations (r^2^=1), according to "Ensembl" database

[^27]: SNP in high LD with rs2288904 for most populations, particularly the European ancestry populations (r^2^\>0.90), according to "Ensembl" database.

[^28]: The data shown in [Table 4](#tbl0004){ref-type="table"} concerning the HUGO nomenclature and the molecular process involved in carcinogenesis were obtained from \"Genecards\" database (exceptions are referenced).
